Mouse Anti-Human CYFRA21-1 monoclonal antibody, clone 2715

In this study, we screened 381 miRNAs by RT-qPCR in serum samples of 44 NSCLC patients and 22 healthy individuals to identify altered miRNAs, and validated the results in a training and test cohorts with 300 serum samples (178 NSCLC and 122 healthy individuals). Three miRNAs (miR-194, miR-652 and miR-660) were selected from 380 miRNAs by two normalization methods in the discovery cohort, and miR-652 and miR-660 were confirmed to be significantly upregulated in ADC and SCC patients compared with healthy controls both in the training and test cohorts (p < 0.01). The combination of miR-652 and miR-660 exhibited significantly higher AUC than miR-660, CEA and CA125 for ADC and SCC diagnosis in both the training and test cohorts (p < 0.05). Furthermore, miR-652 + miR-660 + Cyfra21-1 significantly improved the diagnostic ability to determine ADC patients from healthy controls. For SCC diagnosis, miR-652 + miR-660 + Cyfra21-1 exhibited comparable ability to Cyfra21-1. The results indicate that the combination of miR-652 + miR-660 and Cyfra21-1 has the potential to help in the diagnosis of NSCLC, especially for ADC. (C) 2015 Elsevier Ireland Ltd. All rights reserved.

The aim of this study was to investigate the clinical value of serum cytokeratin 19 fragment (CYFRA21-1) and carcinoembryonic antigen (CEA) in the prediction of chemotherapy response and prognosis in patients with advanced non-small cell lung cancer (NSCLC). Serum CYFRA21-1 and CEA levels of 98 patients with advanced NSCLC were measured using immunoradiometric kits prior to and after 2 cycles of chemotherapy. After 2 cycles of chemotherapy, 45 patients achieved a radiological objective response (OR), 30 patients achieved stable disease (SD) and 23 patients had progressive disease (PD). Serum CYFRA21-1 and CEA were significantly decreased compared to baseline levels (P<0.001). By ROC curve analysis, a >= 60% reduction in CYFRA21-1 and a >= 25% reduction in CEA were the optimal cut-off levels with best sensitivity and specificity for the diagnosis of radiologic OR. The median survival of all patients was 10.2 months (range 2.6-26.3). Univariate survival analysis showed that the Eastern Cooperative Oncology Group (ECOG) performance status (PS) score, radiologic OR, a >= 60% reduction in CYFRA21-1 and a >= 25% reduction in CEA were significant prognostic factors for better overall survival. The median overall survival time in patients with a >= 60% reduction in CYFRA21-1 was significantly longer than in those with a <60% reduction (P<0.001). Similarly, the median overall survival time in patients with a >= 25% reduction in CEA was also significantly longer than in those with a <25% reduction (P<0.001). Multivariate analysis showed that ECOG PS score, a >= 60% reduction in CYFRA21-1 and a >= 25% reduction in CEA were independent prognostic factors of survival, while radiologic OR was not. In conclusion, a >= 60% reduction in CYFRA21-1 and a >= 25% reduction in CEA may be reliable surrogate markers for the prediction of chemothrapy response and prognosis, especially for the diagnosis of radiologic OR.